Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amazon, Hims and hair loss
Hims & Hers Stock Drops After Amazon Says It Will Offer Hair-Loss Treatments
Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and erectile dysfunction, directly competing with the telehealth startup. Amazon on Thursday launched the treatments through its One Medical telehealth service,
Amazon One Medical rolls out telehealth treatment services in competition with Ro, Hims & Hers
Amazon One Medical is rolling out a new service to provide Prime members access to clinical treatments for common health and lifestyle conditions like men's hair loss and anti-aging skin care. | Amazon One Medical is rolling out a new service to provide Prime members access to clinical treatments for common health and lifestyle conditions like men's hair loss and anti-aging skin care.
Amazon launches fixed pricing to treat conditions like hair loss. Hims & Hers stock drops 15%
Amazon announced Prime members can access new upfront pricing to treat five common conditions like erectile disfunction and men's hair loss.
Hims & Hers drops 17% as Amazon rolls out expanded telehealth service
Shares of telehealth services provider Hims & Hers (NYSE:HIMS) fell 17% in morning trading Thursday after Amazon (NASDAQ:AMZN) announced it was launching an expanded pay-per-visit telehealth service,
Amazon One Medical launches service to compete with Hims & Hers
The tech giant said it would offer upfront, monthly pricing for customers seeking consultations and medications for five conditions including erectile dysfunction and men’s hair loss.
54m
on MSN
Hims & Hers’ stock tumbles on Amazon’s latest disruptive foray into healthcare
Hims & Hers Health Inc. shares tumbled 22% Thursday, on concerns that Amazon.com Inc.’s latest push into healthcare will ...
8m
Amazon Gets Into the Boner Pill Business, Hims Stock Goes Limp
Amazon acquired primary care provider One Medical for $3.9 billion in 2022, and fills prescriptions through Amazon Pharmacy.
5h
Amazon's push into telehealth knocks shares of Hims & Hers
Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...
31m
on MSN
These Stocks Are Moving the Most Today: Walt Disney, Super Micro, Cisco, ASML, JD.com, Tapestry, Intuitive Machines, Hims & Hers, and More
Walt Disney’s earnings beat Wall Street estimates, Super Micro Computer extends losses, and Cisco posts fiscal first-quarter ...
5h
Hims & Hers Health Stock Is Tumbling Thursday: What's Going On?
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower in possible response to Amazon.com Inc's (NASDAQ:AMZN) new ...
2h
Hims & Hers cut to underperform by BoA over Amazon competition
BofA lowered its rating of Hims & Hers (HIMS) to underperform from buy, citing Amazon’s (AMZN) push into the hair loss and ...
1h
Hims & Hers under pressure as Amazon launches rival service
Shares of Hims & Hers (HIMS) are sliding on Thursday after Amazon (AMZN) announced the launch of its Amazon One Medical Pay-per-visit ...
Yahoo Finance
2h
Amazon launches lifestyle drug service as challenge to Hims & Hers
The move into lifestyle treatments is seen as a challenge to companies like
Hims
& Hers, which saw its stock value drop ...
Stocktwits on MSN
3h
Hims & Hers Stock’s Retail Army Brushes Off Amazon Medical One’s Rival Service Even As Citi Sees Threat
Shares of Hims & Hers ($HIMS) plummeted nearly 15% on Thursday after Amazon.com, Inc. ($AMZN) launched its new Amazon One ...
1h
Hims & Hers falls -17.7%
Hims & Hers (HIMS) is down -17.7%, or -$4.88 to $22.72. Published first on TheFly – the ultimate source for real-time, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Amazon
Homs
Novo Nordisk
Food and Drug Administration
GLP-1s
Feedback